<DOC>
	<DOCNO>NCT00002059</DOCNO>
	<brief_summary>The objective double-blind placebo-controlled study evaluate effect Isoprinosine group homogenous male volunteer present immunologic defect relative : - Comparison total helper suppressor T-cell number group . - Comparison phytohemagglutinins ( PHA ) concanavalin A lymphoproliferative response natural killer ( NK ) cell activity group . - Determination clinical course volunteer discontinuance Isoprinosine .</brief_summary>
	<brief_title>A Double-Blind Placebo Controlled Study To Determine Optimal Immunopharmacological Dose Level Isoprinosine Immunodepressed Volunteers</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Inosine Pranobex</mesh_term>
	<criteria>Exclusion Criteria Coexisting Condition : Patients follow exclude : Opportunistic infection Kaposi 's sarcoma . Critical illness . History gout , urolithiasis , nephrolithiasis , renal dysfunction , severe gastric ulcer . Concurrent Medication : Excluded : Steroids . Cytotoxic immunosuppressive agent . Concurrent Treatment : Excluded : Radiotherapy . The follow exclude : Opportunistic infection Kaposi 's sarcoma . Critically ill patient . Patients receive steroid , cytotoxic immunosuppressive agent , and/or radiotherapy . Patients receive immunotherapy . Patients history gout , urolithiasis , nephrolithiasis , renal dysfunction , severe gastric ulcer . Prior Medication : Excluded : Any immunotherapy . Patients fall group risk develop cutaneous sarcoma and/or opportunistic disease present sign symptom disease .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 1989</verification_date>
	<keyword>T-Lymphocytes , Suppressor-Effector</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Inosine Pranobex</keyword>
	<keyword>Killer Cells</keyword>
	<keyword>T-Lymphocytes , Helper-Inducer</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
</DOC>